SciSparc's NeuroThera Expands U.S. Patent Portfolio with LSD, Ketamine, and Ibogaine Combinations
SPRC sits 56% above its 52-week low of $2.98.
Summary
NeuroThera, SciSparc's majority-owned subsidiary, announced publication of three new U.S. patent applications covering combinations of PEA with LSD, ketamine, and ibogaine for mental health and substance use disorders. This expands the collaboration with Clearmind Medicine beyond the previously published MDMA-PEA application. The new filings broaden the intellectual property moat around NeuroThera's PEA technology across multiple psychedelic compounds. While still early-stage, the expansion signals continued progress in building a defensible patent portfolio in the emerging psychedelic therapeutics space. Clearmind (CMND) is the collaboration partner but SciSparc is the primary beneficiary through its majority stake in NeuroThera.
At the time of this announcement, SPRC was trading at $4.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $2.98 to $80.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.